Genentech reinvested approximately 21 percent of its operating revenues on a GAAP basis into research and development in 2007 — significantly more than the pharmaceutical industry average. To balance resource use with the strongest likelihood of success, Genentech continuously evaluates its pipeline products in order to determine which are the most promising projects to move through the many phases of clinical testing.
Genentech's development pipeline continues to grow, now numbering more than 100 projects in the following therapeutic focus areas: oncology, immunology, disorders of tissue growth and repair, and neuroscience. The pipeline includes both breakthrough innovations and potential new indications for existing, well-understood products that may fight more than one disease or more than one form of a disease.
Please refer to the product/project links provided below for detailed information regarding the development status of a project.
| FDA Submission Preparation | |
| Avastin® |
First-line metastatic renal cell carcinoma Relapsed glioblastoma multiforme |
| Rituxan® |
Rheumatoid arthritis DMARD-inadequate responders |
| Phase III | |
| 2nd Generation Anti-CD20 | Lupus nephritis Rheumatoid arthritis |
| Avastin |
Adjuvant colon cancer Adjuvant HER2-negative breast cancer Adjuvant HER2-positive breast cancer Adjuvant non-small cell lung cancer Diffuse large B-cell lymphoma First-line advanced gastric cancer First-line HER2-negative metastatic breast cancer First-line HER2-positive metastatic breast cancer First-line metastatic ovarian cancer Gastrointestinal stromal tumors1 High risk carcinoid Hormone refractory prostate cancer Newly diagnosed glioblastoma multiforme1 Metastatic head and neck cancer1 Relapsed platinum-sensitive ovarian cancer Second-line metastatic breast cancer |
| Avastin +/- Tarceva® |
First-line metastatic, non-squamous, non-small cell lung cancer |
| Herceptin® |
Adjuvant HER2-positive breast cancer (HERA 2-year) |
| Lucentis® |
Diabetic macular edema Retinal vein occlusion |
| Pertuzumab |
First-line HER2-positive metastatic breast cancer |
| Rituxan Hematology/Oncology |
Follicular non-Hodgkin's lymphoma Relapsed chronic lymphocytic leukemia |
| Rituxan Immunology |
Active Rheumatoid arthritis ANCA-associated vasculitis Lupus nephritis |
| Tarceva |
Adjuvant non-small cell lung cancer First-line metastatic non-small cell lung cancer |
| Tarceva +/- Avastin |
Second-line metastatic non-small cell lung cancer |
| TNKase® |
Central venous access device occlusion Hemodialysis catheter clearance |
| Xolair® |
Pediatric asthma |
| Phase II | |
| 2nd Generation Anti-CD20 |
Relapsing remitting multiple sclerosis |
| ABT-869 |
Hepatocellular Carcinoma Metastatic Breast Cancer1 Metastatic Colorectal Cancer1 Non-Small Cell Lung Cancer Renal Cell Carcinoma |
| Anti-CD40 | Diffuse large B-cell lymphoma |
| Apomab |
Non-Hodgkin's lymphoma Non-small cell lung cancer |
| Avastin |
Extensive small cell lung cancer Non-squamous, non-small cell lung cancer with previously treated CNS metastases Relapsed multiple myeloma |
| Lucentis |
Diabetic macular edema |
| Pertuzumab | Ovarian cancer |
| Raptiva® | Renal Transplantation1 |
| rhApo2L/TRAIL |
Non-Hodgkin's lymphoma Non-small cell lung cancer |
| Systemic Hedgehog Antagonist |
First-line metastatic colorectal cancer Advanced basal cell carcinoma1 Advanced ovarian cancer1 |
| Trastuzumab-DM1 |
HER2-positive metastatic breast cancer |
| Phase I | |
| 3rd Generation Anti-CD20 |
Chronic lymphocytic leukemia Non-Hodgkin's lymphoma |
| ABT-263 |
Chronic lymphocytic leukemia Lymphoid malignancies Small cell lung cancer |
| Anti-Abeta |
Alzheimer's disease1 |
| Anti-CD4 |
Rheumatoid arthritis |
| Anti-CD40 |
Diffuse large B-cell lymphoma Multiple myeloma Non-Hodgkin's lymphoma |
| Anti-IL13 | Asthma |
| Anti-oxLDL | Secondary prevention of cardiovascular events |
| huMAb OX40L | Asthma |
| IAP Antagonist | Cancer |
| MEK Inhibitor | Cancer |
| MetMAb | Cancer |
| PI3 Kinase Inhibitor | Cancer |
| rhuMAb Beta7 | Inflammatory bowel disease1 |
| rhuMAb IFNalpha | Systemic lupus erythematosus |
| New Molecular Entity | Cancer1 |
| New Molecular Entity (ADC) | Cancer1 |
Information updated August 2008
ADC = Antibody Drug Conjugate; ANCA = Anti-neutrophilic Cytoplasmic Antibodies; CNS = Central Nervous System; DMARD = Disease-modifying Anti-rheumatic Drugs.